Shots: The withdrawal follows the failure of P-III ANNOUNCE study assessing Lartruvo (olaratumab) + doxorubicin followed by Lartruvo as monothx vs doxorubicin + PBO followed by PBO in patients with […]readmore
Tags : Global Market